- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
-
- ANDO Kiyoshi
- Tokai University School of Medicine, Department of Hematology and Oncology
Bibliographic Information
- Other Title
-
- 濾胞性リンパ腫
- 濾胞性リンパ腫 : 最近の動向
- ロホウセイ リンパシュ : サイキン ノ ドウコウ
- —最近の動向—
Search this article
Description
<p>Follicular lymphoma (FL) is a neoplasm comprising germinal center B cells, which typically has, at least, a partially follicular pattern. Although the natural course of the disease is indolent, the chemosensitivity is low, which results in frequent relapse and immunosuppression. Therefore, the tumor stage and tumor burden are essential criteria for deciding on the treatment strategy. For advanced-stage patients with a low tumor burden, watchful waiting is a standard option. The optimal timing for administrating rituximab is a critical clinical question. For advanced-stage patients with a high tumor burden, R-CHOP, R-CVP, and BR are the standard options. Recently, the second-generation CD20 antibody was added to the options. Several new agents are now under development for relapsed FL.</p>
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 59 (10), 2104-2108, 2018
The Japanese Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1390282763058637952
-
- NII Article ID
- 130007496650
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 029282760
-
- PubMed
- 30305515
-
- Text Lang
- ja
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- NDL Search
- PubMed
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed